Marshall Wace
TLX

Marshall Wace’s Telix Pharmaceuticals TLX Stock Holding History

Marshall Wace’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Buy
+189,188
New +$1.93M ﹤0.01% 1815
2026
Q1 		– Sell
-46,658
Closed -$349K – 3774
2025
Q4 		$349K Sell
46,658
-1,915
-4% -$18.4K ﹤0.01% 2392
2025
Q3 		$465K Buy
+48,573
New +$595K ﹤0.01% 2259

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

Marshall Wace's TLX Position: Q2 2026 in Review

Marshall Wace opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 189,188 shares worth $2.18M. The stake represents ﹤0.01% of the portfolio and ranks #1815 among its holdings. This is a return to the name: Marshall Wace previously reported a position in TLX as recently as Q4 2025.

Marshall Wace first reported a position in TLX in Q3 2025 and has held it in 3 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Marshall Wace held 189,188 shares of Telix Pharmaceuticals worth $2.18M as of Q2 2026.
  • Telix Pharmaceuticals was a new Marshall Wace position in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1815 holding.
  • Marshall Wace first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.